COVID19VACCINES AIDS ACTION BALTIMORE Lynda Dee October 6 2021 AAB Town Hall COVID19 Who Gets COVID19 COVID19 Who Gets vaccinated COVID19 Vaccine Update COVID19 Variants and Duration ID: 1044861
Download Presentation The PPT/PDF document "AIDS ACTION BALTIMORE TOWN HALL" is the property of its rightful owner. Permission is granted to download and print the materials on this web site for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.
1. AIDSACTIONBALTIMORETOWN HALLCOVID-19VACCINESAIDS ACTION BALTIMORELynda Dee October 6, 2021
2. AAB Town HallCOVID-19: Who Gets COVID-19 COVID-19 Who Gets vaccinatedCOVID-19 Vaccine UpdateCOVID-19 Variants and DurationCOVID-19 Boosters (Third Vaccine Shot)FDA Vaccine Approval CalendarCOVID-19 Treatment
3. AAB Town HallWho Gets COVID-19; Over 700,000 Deaths1 in 390 Native Americans (or 256.0 deaths per 100,000)1 in 555 Black Americans (or 179.8 deaths per 100,000)1 in 565 Pacific Islander (or 176.6 deaths per 100,000)1 in 665 White Americans (or 150.2 deaths per 100,000)1 in 680 Latino Americans (or 147.3 deaths per 100,000)1 in 1,040 Asian Americans (or 96.0 deaths per 100,000)
4. AAB Town HallWho gets COVID-19 Vaccinations Adults with at least one vaccine dose72% of all US adults71% of Whites70% of Blacks73% of Hispanics
5. AAB Town HallCOVID-19 Vaccines: Pfizer (n= 44,000)FDA Emergency Use Authorization (EUA) 12-10-202 doses, 3 weeks apart97% Efficacy: Symptomatic COVID-1990% in the real world; 2 weeks after second dose Effective against asymptomatic COVID-19 and transmissibilitySide Effects: ISRs, fatigue, headache, muscle pain, nausea most common; chills fever, joint pain less common; anaphylactic shock least common, but most seriousAll side effects worse after second dose; worse in 64 and younger
6. AAB Town HallCOVID-19 Vaccines: Moderna (n= 30,000)FDA Emergency Use Authorization (EUA) 12-17-202 doses 4 weeks apart; storage: 4 degrees below zero96% efficacy in <65; 86% in >652 Weeks after second doseEffective against asymptomatic COVID-19 and transmissibilitySide Effects: ISRs, fatigue, headache, muscle pain, nausea most common; chills fever, joint pain less common; anaphylactic shock least common, but most seriousAll side effects worse after second dose; worse in 64 and younger
7. AAB Town HallCOVID-19 Vaccines: J & J (n= 45,000)FDA EUA: 2-27-21One dose; no storage, transportation or cold chain issuesTrials conducted in US, Argentina, Brazil, Chile, Colombia, Mexico, Peru and South AfricaEfficacy: 72% US, 66% Latin America, 57% South Africa, overall efficacy: 66%; no hospitalizations or deaths in any countrySide Effects: ISRs, fatigue, headache, muscle pain most common; fever, joint pain, diarrhea less common; rash, swollen lymph nodes least common; blood clots which caused a brief EUA pause that severely dampened trust in this vaccine
8. AAB Town HallCOVID-19 Vaccines: Novavax (MD) (n= 15,000)EUA filed but not completed-more data required2 doses; no storage, transportation or cold chain issuesTrials conducted in UK, AU, South Africa, US, MexicoEfficacy: 90%: wild type virus with no variants; 85.6% with United Kingdom variant and 55% with South African variant?Side Effects: ISRs, fever, headache, most common; joint pain, fatigue less common?Side effect reports incomplete: Blood clots?
9. AAB Town HallCOVID-19 Vaccines: AstraZeneca(AZ)/OxfordNo US EUA filing yet; data not yet FDA reviewedEUA in many European countries; one of Europe’s main optionsMired in controversies; temporary holds in many countriesDosage mistake: 1 full dose, one half dose; half dose was better?Transverse myelitis (MS), rare inflammation of the spinal cord?Blood clots definitively determined to be caused by AZ vaccineEfficacy discrepancy: 79 or 76%, 82% with vaccine 12 wks apart?Failure to cooperate with the NIH; DSMB called them out publiclyVery serious credibility issues
10. AAB Town HallVariants: UK, Brazil, SA, CA, NY, DeltaAll viruses mutate to survive, creating what is known as variants/mutations/mistakes; similar to HIV resistanceThe more COVID-19 spreads unchecked, the more it mutates. The more it mutates, the more variants appearVariants may develop quickly in the immunosuppressedVariants also develop in combinationsVariant examples: UK, Brazil and India’s Delta variantDelta variant has overtaken all other variants at this timeTo date, no variant has overtaken vaccines used in the US
11. AAB Town HallDelta VariantDelta variant is more infectious and more deadlySo far, Pfizer, Moderna and J&J vaccines remain effective against Delta variant; .08% of breakthrough casesMost breakthroughs are not causing severe COVID/deathMore and more breakthrough cases are being reportedVariants may eventually overpower our vaccines if more people fail to be vaccinated, thus requiring booster shotsThe search is on for a universal corona virus vaccine
12. AAB Town HallCOVID-19 Vaccine DurationHow long will current vaccines be effective?Will we need boosters (third shots or more)?6-8 months, 1 year???Will COVID-19 require regular vaccines like the flu?All these questions are still being studied
13. AAB Town HallCDC Boosters Recommendation for the Immuno-CompromisedModerately to severely immunocompromised, includingReceiving active cancer treatment for tumors or cancers of the bloodReceived an organ transplant; taking medicine to suppress the immune systemReceived a stem cell transplant within the last 2 yearsPrimary immunodeficiency (such as DiGeorge syndrome, Wiskott-Aldrich syndrome)Advanced or untreated HIV infectionActive treatment with high-dose corticosteroids, other drugs that may suppress immunityPeople should talk to healthcare provider about eligibility, and whether to get boosters
14. AAB Town HallThird Dose Pfizer Booster Approved by FDAACIP/CDC approval is also required for vaccinesPeople >65, 6 mos. after receiving Pfizer vaccinePeople 18 to 64 at high risk of severe COVID-19 High risk of serious complications from frequent institutional or occupational exposureThe two dose Pfizer vaccine regimen was previously fully approved by the FDA
15. AAB Town HallPfizer Booster Approved by CDC>65 and residents in long-term care settings vaccine (ACIP approval)50–64 years with underlying medical conditions (ACIP approval)18–49 years with underlying medical conditions, based on individual benefits and risks (Also approved by CDC Director, overruling ACIP)18-64 years who are at increased risk for COVID-19 exposure and transmission because of occupational or institutional setting, based on their individual benefits and risks (CDC Director approval, overruling ACIP)
16. AAB Town HallMixing and Matching Different VaccinesStudies are underwayNo data is yet availableNo drug companies have yet filed data with the FDASafety and efficacy issues?Dosage issues? Dose timing issues?Second J&J booster, not third doseEffectiveness: 94% against moderate illness?How long after initial dose?
17. AAB Town HallModerna Booster FDA Schedule: 10-14-21Moderna EUA Amendment hearingHow long after initial dose; half the original dose? J&J Booster FDA Schedule: 10-15-21Second J&J booster, not third doseEffectiveness: 94% against moderate illness?How long after initial dose?
18. AAB Town HallPfizer FDA Schedule: 10-26-21EUA Amendment Children 5 to 11SafetyEffectivenessPrevious EUA for children ages 12-15 in May 2021
19. AAB Town HallCOVID-19 Treatment: MolnupiravirMerck is preparing an FDA EUAFirst oral drug for COVID-19 treatment50% risk reduction of hospitalizations and death?7.3% of people on molnupiravir hospitalized or died14.1% of people on placebo a month laterToxicity: Cancer: Risk in pregnancy, reproductive age???
20. AAB Town HallNext Town Hall Zoom MeetingWednesday, November 17, 2021Time: 6:30 to 7:30 PMVirtual meeting
21. Town HallTHANK YOUBaltimore City Health Department
22. AAB Town HallTHANK YOUJeffrey GrabelleAli MoodyFalina Laron Attendees